Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience shares fell after the company announced that its Phase 2b trial for ALTO-100, a treatment for major depressive disorder, did not meet its primary endpoint.
October 22, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alto Neuroscience's stock is negatively impacted as the Phase 2b trial for ALTO-100 did not meet its primary endpoint, leading to a decrease in investor confidence.
The failure to meet the primary endpoint in a clinical trial is a significant setback for a biotech company, as it can delay or halt the development of the drug, affecting future revenue potential. This news likely led to a decrease in investor confidence, causing the stock price to drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100